Radiotherapy With Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients With Stage III-IVB Head and Neck Cancer With a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial

This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Intensity modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. It is not yet know if cetxiumab or chemotherapy, with intensity modulated radiation therapy works best for the treatment of patients with head and neck cancer who are unable to receive cisplatin.

Start Date06 Jan 2027

Sponsor / Collaborator

NRG Oncology

NCT06418724

/ Not yet recruitingPhase 2

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

The NEOPECS trial is a phase II prospective, single-arm, non-randomised interventional trial for patients with borderline resectable locally advanced cutaneous squamous cell carcinoma with a 6-participant safety lead in to ensure safety of the combination in the neoadjuvant setting across 3 sites in Australia.

Start Date30 Jul 2026

Sponsor / Collaborator

Melanoma & Skin Cancer Trials Ltd.

NCT07468071

/ Not yet recruitingPhase 1/2

KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.

Start Date15 Jun 2026

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

100 Clinical Results associated with Cetuximab

100 Translational Medicine associated with Cetuximab

100 Patents (Medical) associated with Cetuximab

7,794

Literatures (Medical) associated with Cetuximab

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Non-Coding RNAs and cernas: emerging modulators of drug response in colorectal cancer

Review

Author: Abkenar, Elahe Daskar ; Sadeghi, Amir ; Mojarad, Ehsan Nazemalhosseini ; Nobili, Stefania ; Shams, Elahe ; Moghani, Mona Malekzadeh ; Sina, Negin ; Ebrahimi, Sara ; Fatemi, Nayeralsadat

Colorectal cancer (CRC) is still one of the most common cancers and a leading cause of cancer morbidity worldwide. A significant issue that should be paid much attention to is its resistance to anticancer agents. Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have been identified as important regulators of drug response and drug resistance in CRC. In this review, we provide a comprehensive assessment of the studies conducted in the field of investigating the role of ncRNAs in drug resistance to prominent anticancer agents used in CRC, including 5-fluorouracil (5-FU), oxaliplatin, cetuximab, bevacizumab, and regorafenib. We focussed specifically on the miRNAs, lncRNAs, and circRNAs associated with resistance to each drug individually, even within the context of combination therapies, such as FOLFOX. We also reviewed competing endogenous RNA (ceRNAs) networks and their relationship with drug sensitivity and resistance and new therapeutic strategies to manage drug resistance in CRC and also analyzed the role of ceRNA networks in modulating drug response and its implications for new approaches to overcome drug resistance in CRC. This article also discusses findings from human clinical trials, highlighting evidence from patient studies that validate the role of targeting ceRNA and ncRNA networks in improving drug sensitivity, overcoming resistance, and enhancing therapeutic outcomes in CRC. It supports the targeting of ncRNA and ceRNA networks as potential therapies to improve treatment outcomes and drug resistance in CRC.

01 Jul 2026·ORAL ONCOLOGY

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial

Article

Author: Kotecki, Nuria ; Attignon, Valéry ; Pérol, David ; Garin, Gwenaelle ; You, Benoît ; Fayette, Jérome ; Wang, Qing ; Lefebvre, Gautier ; Cupissol, Didier ; Tabone-Eglinger, Séverine ; Daste, Amaury ; Peyrade, Frédéric ; Guyennon, Aurélie ; Treilleux, Isabelle ; Digue, Laurence ; Even, Caroline ; Gauduchon, Thibault ; Couchon-Thaunat, Sophie ; Ferlay, Céline ; Tourneau, Christophe Le

BACKGROUND:

The PI3K/AKT pathway activation is an independent marker of poor outcome in head and neck squamous-cell carcinoma (HNSCC), and involved in resistance to cetuximab. Molecular alterations in this pathway, particularly PIK3CA mutations, represent a key event of this dysregulation. Buparlisib is a pan-Class I PI3K inhibitor that inhibits tumor growth in HNSCC xenografts.

METHODS:

This phase II trial evaluated buparlisib (100 mg/d) in two parallel cohorts of refractory HNSCC patients (progression after platinum and cetuximab) with or without PIK3CA mutated in exons 9/20. The primary endpoint was the 2-month Disease Control Rate (DCR2m) as per centrally reviewed. Buparlisib would be considered ineffective if DCR2m ≤ 10% and promising if ≥ 30% (α: 5% unilateral, power: 90%): 7 successes for 35 evaluable patients per cohort were required. Secondary endpoints included ORR, PFS, OS, and safety.

RESULTS:

From January 2013 to July 2018, 58 HNSCC patients received ≥ 1 dose of buparlisib (PIK3CA wild-type, n = 36; PIK3CA-mutated, n = 22); 78% had received ≥ 2 prior lines of systemic therapy. The PIK3CA-mutated cohort was prematurely closed because of slow accrual. The DCR2m was 38.9% (95% CI [25.5- + ∞[) in PIK3CA wild-type and 36.4% (95% CI [19.5 - + ∞[) in PIK3CA-mutated patients. A total of 53.4% of patients experienced treatment-related grade ≥ 3 adverse events. The most frequent (>5%) were hyperglycemia, lymphopenia, asthenia, sodium decrease, depression, and dermatitis. Two toxic deaths were reported.

CONCLUSION:

Although the trial met the primary endpoint, buparlisib monotherapy was associated with unacceptable toxicity and showed limited efficacy in heavily pretreated HNSCC patients.

01 Jul 2026·BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Targeting cancer cell sialylation with monosaccharide analogues modulates EGFR in colorectal cancer cells

Article

Author: Gomes, Joana ; Costa, Ana F ; Rapp, Erdmann ; Gomes, Catarina ; Andújar-Martínez, Ivan ; do Vale, Rosa ; Duarte, Henrique O ; Gotti, Jordan ; Reis, Celso A ; Burock, Robert

Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide, mainly due to resistance to targeted therapies such as Cetuximab, a chimeric monoclonal antibody targeting epidermal growth factor receptor (EGFR) used in RAS wild-type tumours. Aberrant glycosylation, specifically increased sialylation, has been implicated in tumour progression and therapy resistance. However, its role in the response to EGFR-targeted treatment is not fully understood. This study investigates the impact of inhibition of sialylation on CRC cells' malignant properties and on responsiveness to Cetuximab therapy. Three RAS wild-type CRC cell lines with distinct sialylation profiles, including an ST6GalI overexpressing model, were used as models to evaluate the effects of a pan-sialyltransferase inhibitor. Treatment effectively reduced both terminal α2,3- and α2,6-sialylation at the cell surface and induced a global remodelling of the N-glycome, with decreased sialylated and increased neutral glycans. Functionally, sialylation significantly impaired cell motility without affecting cell viability in any of the cell models. Total EGFR expression and basal activation were not altered, while EGFR glycosylation was directly modulated, particularly terminal α2,6-sialylation. Importantly, EGFR sialylation affected Cetuximab binding and receptor activation in a cell line-dependent manner, with cells bearing α2,6-sialylation showing modified antibody responsiveness. Overall, these findings demonstrate that EGFR sialylation modulates receptor behaviour and Cetuximab response in CRC, highlighting the inhibition of sialylation as a potential strategy to overcome glycosylation-mediated therapeutic resistance.

662

News (Medical) associated with Cetuximab

26 May 2026

·www.biospace.com

Pfizer’s BRAFTOVI® Becomes First Pfizer Therapy to Receive Priority Access Under Ontario’s FAST Program, Accelerating Treatment for Canadians with Metastatic Colorectal Cancer

KIRKLAND, QC , May 26, 2026 /CNW/ - Pfizer Canada announces that BRAFTOVI® (encorafenib) will be funded under Ontario's Funding Accelerated for Specific Treatments (FAST) program. Following positive reimbursement recommendation from the Canadian Drug Agency (CDA‑AMC), Ontario is the first province to fund Braftovi® for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test. This announcement is a significant step forward in accelerating access to innovative cancer therapies in Canada. "At Pfizer, we are driven to address priority areas of unmet need for patients," said Cynthia Di Lullo, Oncology Lead, Pfizer Canada. "However, innovation is most impactful when it reaches patients as quickly as possible. The development of BRAFTOVI® is a testament to our commitment in advancing cancer care, and its inclusion in the FAST program is a validation of what's possible when industry, government, and other healthcare stakeholders collaborate to put patients first." Ontario has set an important example with the FAST program, in recognizing the urgency to create a faster and more direct path from regulatory approval to public coverage and improving timely access for cancer patients. "For every Ontarian facing a cancer diagnosis, timely access to high-quality treatment can make all the difference. Through the FAST program, our government is accelerating access to life-saving therapies, including BRAFTOVI®, bringing hope, peace of mind, and transformative care to those who need it most," said Hon. Sylvia Jones, Ontario Deputy Premier and Minister of Health. The announcement also highlights the importance of continued collaboration across leaders in Canada's oncology communities, from governments to healthcare partners to industry to patient advocacy organizations. Ontario's FAST program demonstrates what is possible when shared commitment to patient care turns into action. "Colorectal cancer remains one of the leading causes of cancer-related deaths in Canada. 1 As a colorectal cancer survivor myself, I know the diagnosis can be devastating, and for patients with a BRAF V600E mutation, the prognosis can be particularly challenging," adds Barry Stein, President, Colorectal Cancer Canada. "Accelerated access for cancer therapies in Ontario represents a victory for precision medicine and for the Ontarians who stand to benefit. I look forward to seeing all our other provinces and territories initiate similar programs to accelerate patient access to new cancer therapies with a view to improving patient outcomes" Colorectal cancer is a significant health issue in Canada. In 2025 alone, it was estimated that 26,400 people would be diagnosed and 9,100 would die from the disease, representing 10 per cent of all cancer cases and deaths. 2 "The average wait time for oncology drugs in Canada is approximately 18.9 months, which is simply too long for those navigating a difficult diagnosis," said An Van Gerven, President of Pfizer Canada. "We commend the Government of Ontario and Minister Jones for their strong leadership and commitment to accelerating access to innovative cancer treatments through initiatives like the FAST program. Pfizer is proud to support these efforts and remains committed to working collaboratively to help ensure equitable access for patients in Ontario and across Canada." "For patients diagnosed with metastatic colorectal cancer, every single day counts. The waiting period to receive new treatments can be one of the most stressful parts of the cancer journey," shares Filomena Servidio-Italiano, President and CEO, Colorectal Cancer Resource & Action Network (CCRAN). "This announcement is a step forward for cancer care in Ontario, and perhaps most importantly it delivers tangible progress for patients and their loved ones by easing the burden of unnecessary wait times." Timely access benefits everyone. Faster access to treatment means healthier patients, reduced strain on hospitals and health systems, and can result in stronger health outcomes across the country. Governments nationwide can look to the Government of Ontario as a leading example of how bold, patient-focused reform delivers meaningful improvements in access to care. About BRAFTOVI® BRAFTOVI® (encorafenib) is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test. Clinical data supporting the use of BRAFTOVI ® in the treatment of patients with BRAF V600 mutations are limited to patients with V600E or V600K mutations. BRAFTOVI ® (encorafenib) is indicated, in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy. BRAFTOVI ® (encorafenib) is indicated, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test. BRAFTOVI ® (encorafenib) has been issued market authorization with conditions for this indication, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. About Pfizer Canada Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. At Pfizer, we apply science and our global resources to bring therapies to people that help extend and improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. To learn more about Pfizer Canada, visit pfizer.ca or follow us on LinkedIn , Facebook , Instagram or YouTube . _________________________ 1 2 SOURCE Pfizer Canada Inc.

26 May 2026

·www.biospace.com

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026. “We are excited to have Michael join our Board as he brings more than three decades of experience leading global pharmaceutical and biotechnology companies, with a proven track record of taking oncology medicines from clinical development through successful commercialization, including landmark therapies like ERBITUX®,” said Daniel Paterson, president and chief executive officer of Verastem Oncology. “We look forward to drawing on the insight and expertise Michael brings as we enter the next phase of growth for AVMAPKI® FAKZYNJA® CO-PACK and advance the development of VS-7375, our potential best-in-class oral KRAS G12D (ON/OFF) inhibitor.” “Michael is an accomplished biopharmaceutical executive with deep expertise across the full product lifecycle. Michael’s perspective will be an asset to our Board as Verastem advances its innovative pipeline and builds on its commercial success,” said John Johnson, chairman of Verastem’s Board of Directors. “We’d also like to thank Robert for his dedicated service and the contributions he made during his tenure.” Mr. Bailey added, “I am honored to join Verastem’s Board of Directors at such a pivotal time for the company. Verastem has built a strong business for an underserved rare cancer patient population, and with VS-7375, the company has the potential to make a significant difference in the lives of patients living with KRAS G12D-mutated cancers where there are currently no approved therapies. I look forward to supporting the team and contributing to the company’s continued growth.” Michael P. Bailey Mr. Bailey currently serves as president and chief executive officer (CEO) of AVEO Pharmaceuticals, Inc. (AVEO), an LG Chem, Ltd. Company, and has served on its Board since January 2015, having previously held the roles of chief business officer and chief commercial officer at AVEO. In 2023, Mr. Bailey led the acquisition of AVEO by LG Chem, Ltd. Before AVEO, he was senior vice president of business development and chief commercial officer at Synta Pharmaceuticals Corp. Earlier, Mr. Bailey spent nine years at ImClone Systems Inc., where he led commercial planning and the launch of ERBITUX® (cetuximab) across multiple oncology indications, drove new product planning for CYRAMZA® (ramucirumab) and PORTRAZZA® (necitumumab) and rose to senior vice president of commercial operations. Prior to ImClone, Mr. Bailey managed the cardiovascular new products development portfolio at Genentech. Mr. Bailey started his career as part of SmithKline Beecham’s executive marketing development program, where he held a variety of commercial roles, including sales, strategic planning and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from Mendoza College of Business at University of Notre Dame and continued his executive education in Finance at Harvard Business School and Board of Director Leadership at Wharton School of Business. About Verastem Oncology Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition , FAK inhibition , and KRAS G12D inhibition . For more information, please visit and follow us on LinkedIn . Contacts For Investor and Media Inquiries: Julissa Viana Senior Vice President, Corporate Communications, Investor Relations & Patient Advocacy investors@verastem.com or media@verastem.com

Executive Change

26 May 2026

·www.biospace.com

All eyes on Revolution, bispecific antibodies and more at ASCO26

iStock, Iryna Olkhova Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care. The upcoming American Society of Clinical Oncology annual conference will showcase data that could move the needle for some hard-to-treat cancers and those for which advances have been dormant for decades. Some 40,000 attendees from around the world will gather from May 29 to June 2 at Chicago’s McCormick Place Convention Center to present and discuss the latest innovations in cancer care. The 2026 ASCO meeting will include more than 7,000 abstracts, with studies exploring cutting-edge therapies that experts say could reshape the industry and patient care. “ASCO 2026 is shaping up to be one of the most exciting meetings in years for gastrointestinal oncology,” Allyson Ocean, a medical oncologist at NewYork-Presbyterian and Weill Cornell Medicine, told BioSpace in an email. “For pancreatic cancer specifically, there is a palpable sense at this year’s ASCO that we may be entering a fundamentally different era.” Elsewhere, experts are awaiting data on bispecific antibodies, as well as potentially practice-changing presentations in prostate, lung and blood cancers. Pancreatic cancer in the spotlight Heading into ASCO 2026, all eyes are on Revolution Medicines and pancreatic cancer . The company scored a plenary session spot at the conference for the Phase III RASolute 302 trial, evaluating its RAS inhibitor daraxonrasib against chemotherapy in previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Revolution stunned the cancer world last month when topline data revealed that the pill nearly doubled overall survival , an unprecedented win in a disease with just a 13% 5-year relative survival rate. “This is a huge moment in pancreas cancer,” said Meredith Pelster, associate director of Gastrointestinal Cancer Research at Sarah Cannon Research Institute, who is an investigator on the RASolute trial but not an author on the plenary abstract. “You can feel the excitement.” Daraxonrasib is an oral drug that targets RAS mutations, common in PDAC, non-small cell lung cancer (NSCLC) and colorectal cancer. Patients in RASolute taking daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those on chemotherapy, according to Revolution’s press release . The company’s shares rallied 40% the day of the announcement. Additional RASolute data will be presented on Sunday, and experts are eager for information on the depth of the response, results based on patients’ specific mutations, and more. Pelster is looking to learn more about toxicities, after earlier data showed that the vast majority of patients developed a rash and around 30% had serious side effects. “We just want to understand that, so that we can counsel the patients and know how to manage it appropriately,” Pelster told BioSpace in an interview. Pancreatic cancer Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve on that result with increased tolerability—and more time for patients. May 18, 2026 · 7 min read · Heather McKenzie Read more Adding to the buzz around the gastrointestinal space is the deployment of blood tests for circulating tumor DNA (ctDNA) to help manage patient care. A notable late-breaker will discuss the CIRCULATE trial, which tested using ctDNA to guide decisions for adjuvant treatment in stage II colon cancer. The strategy could spare some patients unnecessary chemotherapy while flagging others who might need more treatment, Ocean said. This year’s ASCO reflects a broader shift toward biomarker-driven precision oncology for gastrointestinal cancers, Ocean said. Other anticipated presentations in the space include trials looking at Pfizer’s Braftovi plus cetuximab and chemotherapy in colorectal cancer, Shanghai KeChow Pharma ’s Tunlametinib plus vemurafenib in colorectal cancer, and Incyte’s Pemazyre in bile-duct cancer. Bispecifics and HARMONi-6 For Leerink Partners analyst Daina Graybosch, the focus is on bispecific antibodies, particularly the Keytruda rival ivonescimab, in development by Summit Therapeutics and its Chinese partner Akeso. Akeso’s closely watched Phase III trial HARMONi-6 also claimed a spot in ASCO’s plenary session. The trial puts the PD-1/VEGF bispecific ivonescimab plus chemotherapy up against BeOne Medicines’ Tevimbra plus chemotherapy as first-line treatment for patients with advanced squamous NSCLC. The session comes on the heels of positive progression-free survival (PFS) data presented at the European Society for Medical Oncology Congress in October 2025. Median PFS was 11.14 months for patients treated with the ivonescimab combo compared to 6.9 months in the comparator group. “The big debate is, what does this look like in overall survival?” Graybosch, senior managing director of immuno-oncology at Leerink, said in an interview with BioSpace . That answer will help determine where ivonescimab and other bispecifics fit in the treatment landscape, she said. “For me, it’s: How much better than Keytruda is it going to be?” Graybosch added. “Then, what does that mean in terms of who is going to have sustainable revenues from a bispecific?” Ivonescimab has the potential to shake up the therapeutic status quo, in which Merck’s blockbuster PD-1 inhibitor Keytruda currently reigns supreme. The asset grabbed attention when it bested Keytruda i n a China-only trial in 2024 in advanced NSCLC. But more recent global trials have missed their marks on PFS overall survival, tempering expectations and raising questions about ivonescimab’s global potential. Lung Cancer Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient populations. May 30, 2025 · 3 min read · Nick Paul Taylor Read more This puts even more pressure on the overall survival data for HARMONi-6, a China-only trial, that will be presented this weekend, Graybosch said. “If you believe that the data is going to degrade in effect from China to a global study, you need to see a really impressive result in China.” Other companies are also showcasing data on PD-1/VEGF bispecifics this weekend. Bristol Myers Squibb and BioNTech have Phase 2 data in NSCLC and Phase 2/3 data in colorectal cancer for their bispecific PD-1/VEGF-A inhibitor pumitamig. Pfizer, meanwhile, has updated Phase 2 data for its PD-1/VEGF bispecific antibody in patients with NSCLC. Practice-changing potential In addition to RASolute302 and HARMONi-6, the other plenary session slots at this year’s ASCO have the potential to shift practice for both common and rare cancers, experts said. One such trial could help determine whether oncologists should add Johnson & Johnson’s androgen receptor inhibitor ERLEADA before and after surgery for patients with high-risk localized prostate cancer. The LIBRETTO-432 trial will analyze event-free survival with Eli Lilly’s Retevmo in stage IB-IIIA RET fusion-positive NSCLC in the adjuvant setting, to see whether the drug should move from advanced to earlier-stage disease. And the Phase III SARC041 trial is testing Lilly’s CDK4 inhibitor Verzenio in a rare, difficult-to-treat sarcoma called dedifferentiated liposarcoma (DDLS). Another notable late-breaker with the potential to change practice is a Phase III study of Incyte’s anti-CD19 monoclonal antibody Monjuvi/Minjuvi plus lenalidomide and R-CHOP chemotherapy vs. current R-CHOP standard of care in newly diagnosed patients with diffuse large B cell lymphoma (DLBCL). “The first-line treatment of diffuse large B cell lymphoma has not been changed for a couple of decades,” Andres Sirulnik, head of the Hematology Clinical Development Unit at Regeneron, told BioSpace . “People are waiting to see the results.” Regeneron is presenting its own data in frontline DLBCL, an early readout of its bispecific antibody Ordspono plus chemotherapy in the Phase III OLYMPIA-3 trial. The treatments could offer patients a shorter, less cumbersome regimen, Sirulnik said. “We are hoping that this also will translate to better outcomes.”

Phase 3ASCOClinical ResultPhase 2

100 Deals associated with Cetuximab

External Link

KEGG	Wiki	ATC	Drug Bank
D03455	Cetuximab	L01XC06	DB00002

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
BRAF V600E mutant Colorectal Cancer	China	Merck Europe BV	30 Sep 2025
RAS Wild Type Colorectal Cancer	Australia	Merck Healthcare Pty Ltd.	25 Sep 2007
Head and Neck Neoplasms	United States	Eli Lilly & Co.	01 Mar 2006
Head and Neck Neoplasms	United States	ImClone LLC	01 Mar 2006
Metastatic Colorectal Carcinoma	European Union	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	Iceland	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	Liechtenstein	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	Norway	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	European Union	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	Iceland	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	Liechtenstein	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	Norway	Merck Europe BV	29 Jun 2004
Colorectal Cancer	Switzerland	Merck & Co., Inc.	01 Dec 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colonic Cancer	Phase 3	United States	Merck Sharp & Dohme LLC	16 Jul 2025
Colonic Cancer	Phase 3	China	Merck Sharp & Dohme LLC	16 Jul 2025
Colonic Cancer	Phase 3	Japan	Merck Sharp & Dohme LLC	16 Jul 2025
Colonic Cancer	Phase 3	Argentina	Merck Sharp & Dohme LLC	16 Jul 2025
Colonic Cancer	Phase 3	Australia	Merck Sharp & Dohme LLC	16 Jul 2025
Colonic Cancer	Phase 3	Brazil	Merck Sharp & Dohme LLC	16 Jul 2025
Colonic Cancer	Phase 3	Canada	Merck Sharp & Dohme LLC	16 Jul 2025
Colonic Cancer	Phase 3	Chile	Merck Sharp & Dohme LLC	16 Jul 2025
Colonic Cancer	Phase 3	Colombia	Merck Sharp & Dohme LLC	16 Jul 2025
Colonic Cancer	Phase 3	Finland	Merck Sharp & Dohme LLC	16 Jul 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05004350 (NAUTICAL CRC \| NAUTICAL \| NAUTICALCRC, CTgov)	Phase 2	BRAF V600E mutant Colorectal Cancer \| Metastatic Colorectal Carcinoma	107	Cetuximab (CETUX)+Encorafenib (ENCO) (Safety Lead-in Phase: ENCO + CETUX)	ikmupdmedf = zlfntxcoii kwqjuqrrft (ndnkezoxao, jphlwozuka - gvtpdvnwnj) View more	-	30 Apr 2026
				Cetuximab (CETUX)+Encorafenib (ENCO) (Randomized Phase: ENCO + CETUX)	cmnwcahpvx(apwkbpacnr) = gysmmbtvft oxixrhvmbw (fgpwqarijy, hhiiuhzbqq - jwbhypfraw) View more
NRG-HN004 (AACR2026)	Not Applicable	Squamous Cell Carcinoma of Head and Neck	6,299	Radiation with chemotherapy (RT-C)	yzdqkdcxon(eepxzrnyfz) = ltotlyazkx mcupbpvgbm (dbdzedqvsr, 63.8 - 66.3) View more	Negative	22 Apr 2026
				Radiation with immunotherapy (RT-I)	yzdqkdcxon(eepxzrnyfz) = jetqmwjkup mcupbpvgbm (dbdzedqvsr, 49.2 - 57.0) View more
AACR2026	Not Applicable	BRAF V600E mutant Colorectal Cancer Second line BRAF-V600E mutation \| WEE1 expression	15	Encorafenib plus cetuximab with or without binimetinib (high-WEE1)	qkdxjttzko(wlsibplqpx) = vbmiqgfjlk pgwrftubtm (ogyhlzthqu )	Positive	22 Apr 2026
				Encorafenib plus cetuximab with or without binimetinib (low-WEE1)	qkdxjttzko(wlsibplqpx) = ysfvpazhac pgwrftubtm (ogyhlzthqu )
SWOG S0819 (AACR2026)	Phase 3	Non-Small Cell Lung Cancer Serial CTRS	1,275	Cetuximab + carboplatin/paclitaxel	icgbcedxlf(crgmrbofvl) = BOR achieved 35% (33–37%) power tztkvwymmi (nwfokujwar ) View more	Positive	20 Apr 2026
				Bevacizumab + cetuximab + carboplatin/paclitaxel
NCT05756153 (KROCUS, Pubmed \| Lancet Oncol)	Phase 1/2	KRAS mutant Non-small Cell Lung Cancer First line KRAS G12C	47	Fulzerasib 600 mgCetuximab 500 mg/m² + Fulzerasib 600 mgCetuximab 500 mg/m² (KRAS G12C-mutated NSCLC)	cutewmtopg(mmclyrsjfc) = chjjormyyk gkebvhnuld (ashsgnzunr, 56 - 80) View more	Positive	01 Apr 2026
NCT05004350 (NAUTICAL, Pubmed \| Cancer Med)	Phase 2	BRAF V600E mutant Colorectal Cancer BRAF V600E	107	Encorafenib and Cetuximab	sszsnwutej(qhioidvmid) = xhsowshdzp xrvdnwalle (ydjtcsickb ) View more	Positive	01 Mar 2026
				Irinotecan/Cetuximab or FOLFIRI /Cetuximab	sszsnwutej(qhioidvmid) = cmjfrhvcbg xrvdnwalle (ydjtcsickb ) View more
NCT03693807 (CTgov)	Phase 2	Colorectal Liver Metastases \| Colorectal Cancer \| Bile Duct Neoplasms	35	Cetuximab+Gemcitabine+Floxuridine (FUDR)+Oxaliplatin+Irinotecan (CPT-11)+Panitumumab+Fluorouracil (Group 1: Unresectable Liver Metastases From Colorectal Cancer)	imcuxhhmbc(rtkvjfqlls) = uhpgftciyw jksxztjxww (xkkazdwyyt, lrlbyvhxow - wukeapfllm) View more	-	06 Feb 2026
				Cetuximab+Gemcitabine+Floxuridine (FUDR)+Oxaliplatin+Irinotecan (CPT-11)+Panitumumab+Fluorouracil (Group 2: Resectable Liver Metastases From Colorectal Cancer)	imcuxhhmbc(rtkvjfqlls) = yatbbnfhow jksxztjxww (xkkazdwyyt, vmbgcfzgsl - wwftmdffrq) View more
NCT02979977 (Phase 2 trial of dual EGFR inhibition with cetuximab and afatinib, CTgov)	Phase 2	Advanced Head and Neck Squamous Cell Carcinoma	50	Afatinib+cetuximab	hxotydoeva(idspdpgyrl) = eejbvkrgyp gnsgbsgsen (avqpjwrfnk, hsdurrxwbo - tgxacmmuki) View more	-	04 Feb 2026
NCT04587128 (ASCO_GI2026)	Phase 2	Metastatic Colorectal Carcinoma First line RAS/RAF wildtype	21	Panitumumab or Cetuximab	kpfoiyqlyl(mcvxygkepj) = bacduhadbv yjekwlsnjb (vxrizeaqbq ) View more	Positive	08 Jan 2026
NCT06358430 (ASCO_GI2026)	Phase 1	Colorectal Cancer	14	TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells+cetuximab	nyeibbxvyz(ikjeykeuoj) = wfhkwjynjq wbxgtfjvyn (pzenidxpuz ) View more	Positive	08 Jan 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis